文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

序贯CD7 CAR-T细胞治疗与异基因HSCT(不进行GVHD预防)

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
PubMed 文献 · N Engl J Med · 2024-01-01
一句话结论10例复发/难治CD7阳性白血病或淋巴瘤患者接受序贯CD7 CAR-T与单倍体HSCT、不做药物清髓和GVHD预防,1年总生存68%,作者认为安全有效。

该研究纳入10例复发/难治CD7阳性白血病或淋巴瘤患者,采用「all-in-one」策略:先给予CD7 CAR-T细胞治疗,在达到血细胞未完全恢复的完全缓解后,直接进行单倍体HSCT,不做药物清髓、不用GVHD预防药物。CAR-T后10例均达血细胞未完全恢复的完全缓解并出现4级全血细胞减少;HSCT后1例第13天死于脓毒性休克和脑炎,8例达完全供者嵌合,1例自体造血,3例发生2级HSCT相关急性GVHD。中位随访15.1个月,6例维持MRD阴性完全缓解,2例CD7阴性白血病复发,1例3.7个月死于脓毒性休克;估计1年总生存68%(95%CI 43–100),1年无病生存54%(95%CI 29–100)。作者认为该策略安全有效,为不适合常规异基因HSCT的CD7阳性肿瘤患者提供可行途径。

要点

  • 10例复发/难治CD7阳性白血病或淋巴瘤患者接受序贯CD7 CAR-T后单倍体HSCT,不做药物清髓和GVHD预防。
  • CAR-T后10例均达血细胞未完全恢复的完全缓解,均出现4级全血细胞减少。
  • HSCT后8例达完全供者嵌合,1例自体造血,3例发生2级HSCT相关急性GVHD。
  • 中位随访15.1个月(范围3.1–24.0),6例维持MRD阴性完全缓解,2例CD7阴性白血病复发。
  • 估计1年总生存68%(95%CI 43–100),1年无病生存54%(95%CI 29–100)。

适用人群与场景

  • 复发或难治性CD7阳性白血病或淋巴瘤患者10例。
  • 作者认为该策略适用于不适合常规异基因HSCT的CD7阳性肿瘤患者。

处置流程与药物剂量

  • 先给予CD7 CAR-T细胞治疗;在CAR-T诱导达血细胞未完全恢复的完全缓解后,序贯进行单倍体HSCT,不做药物清髓、不使用GVHD预防药物。

红旗征与不能漏的情况

  • HSCT后1例于第13天死于脓毒性休克和脑炎。
  • 1例于3.7个月死于脓毒性休克。
  • CAR-T后10例均出现4级全血细胞减少。
  • 3例发生2级HSCT相关急性GVHD。

研究设计与关键结果

  • 研究类型:单臂研究,纳入10例复发或难治性CD7阳性白血病或淋巴瘤患者,采用序贯CD7 CAR-T与单倍体HSCT、不做药物清髓和GVHD预防的「all-in-one」策略。
  • CAR-T后:10例全部达血细胞未完全恢复的完全缓解,全部出现4级全血细胞减少。
  • HSCT后:1例第13天死于脓毒性休克和脑炎,8例达完全供者嵌合,1例为自体造血,3例发生2级HSCT相关急性GVHD。
  • 随访:CAR-T后中位随访15.1个月(范围3.1–24.0),6例维持MRD阴性完全缓解,2例CD7阴性白血病复发,1例3.7个月死于脓毒性休克。
  • 估计1年总生存68%(95%CI 43–100),估计1年无病生存54%(95%CI 29–100)。

证据类型、等级与局限

  • 证据类型:单臂研究(10例),作者结论为「我们的发现提示」序贯CD7 CAR-T与单倍体HSCT安全有效,缓解与严重但可逆的不良事件。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,序贯CD7 CAR-T细胞治疗与单倍体HSCT、不做药物清髓和GVHD预防,是安全有效的, remission与严重但可逆的不良事件并存。
  • 作者认为,该策略为不适合常规异基因HSCT的CD7阳性肿瘤患者提供了可行途径。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control is unclear.

METHODS: We tested a novel "all-in-one" strategy consisting of sequential CD7 CAR T-cell therapy and haploidentical HSCT in 10 patients with relapsed or refractory CD7-positive leukemia or lymphoma. After CAR T-cell therapy led to complete remission with incomplete hematologic recovery, patients received haploidentical HSCT without pharmacologic myeloablation or GVHD prophylaxis drugs. Toxic effects and efficacy were closely monitored.

RESULTS: After CAR T-cell therapy, all 10 patients had complete remission with incomplete hematologic recovery and grade 4 pancytopenia. After haploidentical HSCT, 1 patient died on day 13 of septic shock and encephalitis, 8 patients had full donor chimerism, and 1 patient had autologous hematopoiesis. Three patients had grade 2 HSCT-associated acute GVHD. The median follow-up was 15.1 months (range, 3.1 to 24.0) after CAR T-cell therapy. Six patients remained in minimal residual disease-negative complete remission, 2 had a relapse of CD7-negative leukemia, and 1 died of septic shock at 3.7 months. The estimated 1-year overall survival was 68% (95% confidence interval [CI], 43 to 100), and the estimated 1-year disease-free survival was 54% (95% CI, 29 to 100).

CONCLUSIONS: Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This strategy offers a feasible approach for patients with CD7-positive tumors who are ineligible for conventional allogeneic HSCT. (Funded by the National Natural Science Foundation of China and the Key Project of Science and Technology Department of Zhejiang Province; ClinicalTrials.gov numbers, NCT04599556 and NCT04538599.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Hu Y, Zhang M, Yang T, et al. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. N Engl J Med. 2024. PMID: 38657244. doi:10.1056/NEJMoa2313812

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。